Idenix drug does very well in study

7:02AM Idenix Pharma says Valopicitabine combined with standard of care cleared Hepatitis C virus in 72% of patients who completed 12 weeks of treatment (IDIX) 7.23 : Co announces results from a phase II study designed to evaluate triple combination therapy, consisting of valopicitabine, the co's lead drug candidate for the treatment of hepatitis C, pegylated interferon and ribavirin compared to pegylated interferon and ribavirin. This study demonstrated no pharmacokinetic or pharmacodynamic drug-drug interaction between valopicitabine and ribavirin. The triple combination showed consistently higher rates of HCV PCR-negativity, defined as serum HCV RNA levels below 20 copies/mL, compared to the standard of care at every point analyzed in this study. Additionally, the tolerability of the triple combination was satisfactory, with only three discontinuations from the study.

[orleans]

WHY are there no responces to this post? Any links to check this out.